Sinmary To test the hypothesis that high levels of endogenous oestrogens increase the risk for developing breast cancer, concentrations of oestrone, oestradiol and oestriol were measured in 24 h urine samples from 1000 women partipants in a prospective study of breast cancer on the island of Guersey. Sixty-nine subjects were diagnosed with breast cancer subsequent to urine collection. Among women who were premenopausal at the time of urine collection, cases excreted less oestrogen than controls; the odds ratios (95% Cl) for breast cancer in the middle and upper thirds of the distribution of oestrogen excretion, in comparison with the lower third (reference group, assigned odds ratio= 1.0), were 0.5(0.2-1.2) and 0.4(0.2-1.1) respectively for oestrone, 0.8(0.4-1.8) and 0.4(0.2-1.1) for oestradiol, 0.7(0.3-1.6) and 0.7(0.3-1.6) for oestriol and 0.9(0.4-2.0) and 0.5(0.2-1.3) for total oestrogens. Among women who were post-menopausal at the time of urine collection, the trend was in the opposite direction, with an increase in risk associated with increased oestrogen excretion; the odds ratios were 0.9(0.3-2.2) and 1.1(0.5-2.8) for oestrone, 0.8(0.3-2.3) and 1.9(0.8-4.6) for oestradioL 1.5(0.6-3.9) and 1.8(0.7-4.6) for oestriol and 0.9(0.4-2.6) and 1.9(0.7-4.7) for total oestrogens. The trends of increasing risk with increasig oestrogen excretion among post-menopausal women were statistically significant for oestradiol (P=0.022) and for total oestrogens (P=0.016). We conclude that high levels of endogenous oestrogens m post-menopausal women are associated with increased breast cancer risk, but that the relationship of oestrogens in premenopausal women with risk is unclear.
The hypothesis that high levels of endogenous oestrogens may increase breast cancer risk has existed for at least 30 years, but has still not been firmly established. In a review of 32 studies published up until 1987, we concluded that postmenopausal breast cancer cases are exposed to more endogenous oestrogen than controls (Key and Pike, 1988) , and more recent studies have in general supported this conclusion. In two small case-control studies, Bernstein et al. (1990a) and Zaridze et al. (1992) reported higher oestradiol levels in cases than in controls among postmenopausal women. Two small prospective studies found similar oestradiol levels in women who subsequently developed breast cancer and control women (Garland et al., 1992; Helzlsouer et al., 1994) , but a large prospective study of post-menopausal women found a significant increase in risk associated with increased serum concentrations of oestradiol, and particularly of free oestradiol (Toniolo et al., 1995) .
The position is less clear among premenopausal women (Key and Pike, 1988) . Recent case-control studies have reported higher oestradiol levels in cases than in controls (Bernstein et al., 1990b; Zaridze et al., 1992) . However, of the two recent prospective studies with information for premenopausal women, Helzlsouer et al. (1994) reported higher follicular but lower luteal oestradiol in women who subsequently developed breast cancer than in controls, while Rosenberg et al. (1994) reported almost identical oestradiol levels in cases and controls (although further adjustments for stage of cycle by modelling suggested that oestradiol was on average non-significantly higher in cases).
The results reported here are from a prospective study of hormones and breast cancer on the island of Guernsey. Previous analyses of this cohort have suggested that women who subsequently develop breast cancer have a higher proportion of serum oestradiol unbound to proteins (Moore et al., 1986) , but that breast cancer risk is not associated with serum prolactin concentrations . In this report we used the urine samples collected from women in the Guernsey study to estimate urinary excretion of the three classical oestrogens; oestrone, oestradiol and oestriol. between urine collection and the beginniung of their next menstrual period. For the planned analysis of urinary oestrogens in relation to cigarette smoking. the samples selected for assay wAere those for all women who were current smokers: for premenopausal women an additional selection criterion was that urine samples had been collected either between 3 and 11 days after the onset of the last menstruation (follicular phase) or between 11 and 3 days before the onset of the next menstruation (luteal phase). Samples for comparison were from women who were known to be non-smokers at recruitment but who met the other criteria. randomly sampled to give a ratio of non-smokers to smokers of approximately 2:1 among premenopausal women and approximatelIy 3:1 among post-menopausal women. For both planned analyses eligibility was restricted to women who were premenopausal or naturally post-menopausal and were not using exogenous sex hormones at the time of recruitment.
Owing to changing circumstances in the laboratories involved, there was a delay of several years before all the samples were aliquoted. sent to Melbourne and assayed (see below). During this time new cases of breast cancer were ascertained. both among controls in the planned matched case -control study and among the women selected for the planned study of the association of cigarette smoking with oestrogen excretion. It was therefore decided to treat the 1000 women for whom assays were conducted as the total study group and to conduct an unmatched analysis of urinary oestrogens and breast cancer. using all cases of breast cancer ascertained by December 1994.
Assays
Urine samples were considered to be incomplete if the 24 h urine volume was less than or equal to 633 ml. the lower limit of the 95/00 reference interval in 51 women studied by Bingham et al. (1988) . Aliquots of urine, identified by code numbers. were sent frozen to the University of Melbourne.
where urinary concentrations of oestrone. oestradiol and oestriol were measured during 1989 and 1990 using a method involving spectrophotofluorimetrv and internal radioactive standards (Brown. 1976 (Table II) . Table V shows the results of other studies (four prospective, 16 case-control) of urinary or plasma oestrogens in premenopausal breast cancer cases and controls, divided according to the stage of the cycle at which samples were collected. The results are expressed as the ratio of the mean value in cases to the mean value in controls. The pattern is not consistent, but it may be noted that for all the samples collected in the follicular phase the ratio of the mean value in cases to that in controls was equal to or greater than one, whereas for the luteal phase samples 6 out of the 14 ratios reported were less than one. The relationship of oestrogen levels in premenopausal women with breast cancer risk is still unclear, but future studies may benefit from considering results in relation to the stage of the menstrual cycle at which samples are collected.
For post-menopausal women, the current study supports the evidence from prior studies suggesting that high oestrogen levels are directly associated with breast cancer risk. The differences between cases and controls were slightly reduced by adjusting for Quetelet's index, as also reported by Toniolo et al. (1995) . However, because our hypothesis is that high oestrogen levels in post-menopausal women increase breast cancer risk, and that obesity is associated with risk because it is one determinant of oestrogen levels (Grodin et al., 1973; Judd et al., 1982) , we do not think that it is appropriate to adjust our results for Quetelet's index. We therefore conclude that high levels of endogenous oestrogens are associated with increased breast cancer risk in post-menopausal women.
One area of potential concern in the current study is the method of selecting the study group of 1000 women for whom assays were completed. As described above, this comprised the sum of two studies planned in 1986, a matched case-control study of breast cancer risk and a study of the effects of cigarette smoking. Treating all these subjects as one study group and conducting an unmatched analysis of oestrogens and breast cancer risk gives the major benefit of increasing the number of cases from 33 to 69. It could be argued that the assembling of controls in two ways might have introduced some bias. There is certainly some overrepresentation of cigarette smoking among the controls (29% current smokers among women with known smoking status in this analysis, compared with 21% current smokers among all women in the Guernsey cohort with known smoking status), but analysis of the relationship of cigarette smoking with urinary oestrogen excretion did not show any differences in total oestrogen excretion (although there was a 19% reduction in excretion of oestriol (P=0.046) in postmenopausal smokers; Key et al., in preparation). To 1619ĩ nvestigate whether the structure of the study group may have altered the results we also analysed the data according to the original matching; the results were compatible with those reported here, for example the odds ratios in the top third of the distribution were 0.1, 0.1 and 0.5 for oestrone, oestradiol and oestriol respectively in premenopausal women and 0.7, 1.4 and 1.8 in post-menopausal women, all with wide confidence intervals. We think that it is likely that any disadvantages of the method of assembling the study group are outweighed by the advantage of the much larger number of cases available in the unmatched analysis.
